Abbott registers Cephea mitral valve trial; BALANCE TAVI study still not yet recruiting
Abbott Medical Devices listed the CROWN-MV trial of its Cephea Mitral Valve System, while a separate Hamburg-Eppendorf trial comparing TAVI valve designs remains unopened.
This week's notable item for Abbott is a newly registered pivotal trial of its transcatheter mitral valve device, alongside continuing status on a collaborator trial.
- Abbott Medical Devices registered "CROWN-MV" (NCT07798726), a global, non-randomized, multi-center study of the Cephea Mitral Valve System in subjects with symptomatic mitral valve disease who are deemed unsuitable for surgery and transcatheter repair.1 The study is recruiting, with an actual start date of 2026-10-21, and plans to enroll 565 participants estimated across cohorts for mitral regurgitation and mitral annular calcification.1 The primary effectiveness endpoint is freedom from all-cause mortality and heart failure hospitalization at 12 months post index procedure.1 So far the trial lists a single U.S. site, Ascension Via Christi Hospitals Wichita in Kansas.1
- The "BALANCE" trial (NCT07794306), sponsored by Universitätsklinikum Hamburg-Eppendorf, remains not yet recruiting as of the record's last update on 2026-08-31. The study is designed to compare TAVI with either a Meril balloon-expanding intraannular transcatheter heart valve or an Abbott self-expanding intraannular transcatheter heart valve2, with an estimated start date of 2026-10-26 and planned enrollment of 510 participants.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.